Enhancing myocardial plasmid expression by retrograde coronary venous delivery

Catheterization and Cardiovascular Interventions

Volumn 65, Issue 4, 2005, Pages 528-534

  Youssef, Eyas Al Shaykh ^a   Zhang, Ping ^a   Rogers, Pamela I ^a   Tremble, Patrice ^b   Rokovich, Joe ^b   Johnstone, Brian H ^a   March, Keith L ^a,c   Hou, Dongming ^a,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EDWARDS LIFESCIENCES   (United States)

^c RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary venous; Gene delivery; Myocardium; Plasmid

Indexed keywords

BETA GALACTOSIDE;

ANIMAL EXPERIMENT; BALLOON CATHETER; CORONARY VEIN; ENZYME ACTIVITY; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; HEART DISEASE; HEART LEFT VENTRICLE WALL; HYPERBARISM; HYPOBARISM; INTRACARDIAC DRUG ADMINISTRATION; MALE; NONHUMAN; PLASMID; REVIEW; SWINE;

ANIMALS; BETA-GALACTOSIDASE; BLOOD PRESSURE; CORONARY CIRCULATION; CORONARY VESSELS; DISEASE MODELS, ANIMAL; FEMALE; HEART VENTRICLES; HUMANS; MALE; MODELS, CARDIOVASCULAR; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PLASMIDS; SWINE;

EID: 23044478616     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20450     Document Type: Review

References (30)

1. WHO. World health report. Geneva: WHO; 2001.
2. Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002;136:54-71.
3. Schoehel FC, Frazier OH, Jessurun GA. Refractory angina pectons in end-stage coronary artery disease: evolving therapeutic concepts. Am Heart J 1997;134:587-602.
4. Almeda FQ, Parrillo HE, Klein LW. Alternative therapeutic strategies for patients with severe end-stage coronary artery disease not amenable to conventional revascularization. Catheter Cardiovasc Interv 2003;60:57-66.
5. Panchal V, Kalaria V, Breall JA, March KL. Catheter-based therapy for angiogenesis. Appl Imaging Cardiac Interv 2002; Oct., Special Issue.
6. Isner JM, el al. Myocardial gene therapy. Nature 2002;415:234-239.
7. Losordo DW, Vale RP, Isner JM. Gene therapy for myocardial angiogenesis. Am Heart J 1999;138:S132-S141.
8. Simons M, Bonow RO, Chronos NA. Clinical trials in coronary angiogenesis: issues, problems, consensus. Circulation 2000; 102:E73-E86.
9. Britten MB, et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 2003;108: 2212-2218.
10. Assmus B, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002;106:3009-3017.
11. Grines CL, et al. Angiogene GENe Therapy (AGENT-2) study group. A randomized, double blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003;42:1339-1347.
12. Henry TD, et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003; 107:1359-1365.
13. Ruel M, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002;124:28-34.
14. Losordo DW, Vale PR, Symes JF. Angiogenesis gene therapy: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98:2800-2804.
15. Rosengart TK, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100: 468-474.
16. Symes JF. Focal angiogenic therapy for myocardial ischemia. J Cardiol Surg 2000;15:283-290.
17. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000;355:213-222.
18. Vale PR, et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000; 102:965-974.
19. Hou DM, March KL. A novel percutaneous technique for accessing the normal pericardium: a single-center successful experience of 53 porcine procedures. J Invas Cardiol 2003;15:13-17.
20. Waxman S, Pulerwitz TC, Rowe KA, Quist WC, Verrier RL. Preclinical safety testing of percutaneous transatrial access to the normal pericardial space for local cardiac drug delivery and diagnostic sampling. Catheter Cardiovasc Interv 2000;49:472-477.
21. Laham RJ, Simons M, Hung D. Subxyphoid access of the normal pericardium: a novel drug delivery technique. Catheter Cardiovasc Interv 1999;47:109-111.
22. Macris MP, Igo SR. Minimally invasive access of the normal pericardium: initial clinical experience with a novel device. Clin Cardiol 1999;22(1 Suppl 1):136-139.
23. Hou DM, et al. Efficient myocardial delivery of microspheres and endothelial cells via selective retrograde coronary venous delivery. J Am Coll Cardiol 2002;39:A76.
24. Hou DM, et al. Widespread regional myocardial transfection by plasmid encoding Del-1 following retrograde coronary venous delivery. Catheter Cardiovasc Interv 2003;58:207-211.
25. Boekstegers P, Von Degenfeld G, Giehrl W. Myocardial gene transfer by selective pressure regulated retroinfusion of coronary veins. Gene Ther 2000;7:232-240.
26. Herity NA, Lo ST, Oei F. Selective regional myocardial infiltration by the percutaneous coronary venous route: a novel technique for local drug delivery. Catheter Cardiovasc Interv 2000; 51:358-363.
27. Fearon WF, et al. Evaluation of high-pressure retrograde coronary venous delivery of FGF-2 protein. Catheter Cardiovasc Interv 2004;61:422-428.
28. Thompson C, Nasser B, Makower J. Percutaneous transvenous cellular cardiomyoplasty: a novel nonsurgical approach for myocardial cell transplantation. J Am Coll Cardiol 2000;39:75A.
29. Bonnerot C, et al. A β-galactosidase hybrid protein targeted to nuclei as a marker for developmental studies. Proc Natl Acad Sci USA 1987;84:6795.
30. Meisel E, et al. Investigation of coronary venous anatomy by retrograde venography in patients with malignant ventricular tachycardia. Circulation 2001;104:442-447.